Are you suggesting the results aren't good? I don't think anyone here thinks that 42x will reduce OSA completely. It doesn't need to, even CPAP machines do not make that claim.
There's plenty of data on CPAP usage and corresponding AHI reduction. Here are some examples:
CPAP reduces moderate OSA by 33-48%CPAP can reduce severe OSA by 73%Noting that a 73% reduction is only achievable when CPAP is used for more than 6 hours a night, and 30-50% of users give up using CPAP machines entirely.
42x has shown to reduce severe OSA by up to 80% (25% of participants achieved these results), with 63% of participants achieveing a reduction of 50%. I would say these are at least comparable to CPAP, though of course larger trials are required to refine this performance data.
Surely there is a market for this drug, and 42x is surely a threat to take some % of the OSA market away from CPAP treatment?
I'm interested to know your reasoning if you think the data isn't positive. Genuinely